A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patel, D. M.
- Formulation and Evaluation of Buccal Adhesive Drug Delivery System of Lercanidipine
Authors
1 Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
2 Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, Gujarat, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 2, No 2 (2010), Pagination: 164-168Abstract
The purpose of this research was to study buccal adhesive drug delivery system (BADDS) of Lercanidipine using the bioadhesive polymers sodium alginate (Na-alginate) and HPMC K4M along with ethyl cellulose as an impermeable backing layer. BADDS was evaluated by weight uniformity, thickness, drug content, mucoadhesive strength, swelling, in vitro drug release and in vitro drug permeation studies. Mucoadhesive strength (MS) was measured by using a modified apparatus. BADDSs containing Sodium alginate and HPMC K4M at the ratio of 1:2 showed higher MS (34.15 g) with chicken mucosa when compared with 1:1 (28.69 g), 2:1 (24.69 g), ratios, respectively. The swelling index was proportional to Na-alginate content and inversely proportional to HPMC K4M content. The formulation F4 was optimized based on good bioadhesive strength (28.69 g) and sustained in vitro drug permeation (99.04 for 12 hours).It can be concluded that BADDS is a superior, novel system that overcomes the drawback associated with the conventional buccal adhesive tablet.Keywords
Mucoadhesion, Buccal Drug Delivery, Lercanidipine, Sodium Alginate, HPMC K4M.- Design and Evaluation of Modified Release Dosage Form Containing Bupropion Hydrochloride
Authors
1 Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
2 Parul Institute of Pharmacy, Baroda-391760, IN
3 Shri Sarvajanik Pharmacy College, Near Arvind Baug, Mehsana-384 001, IN
Source
Research Journal of Pharmaceutical Dosage Form and Technology, Vol 2, No 1 (2010), Pagination: 47-51Abstract
In the present investigation an attempt was made to reduce the frequency of dose administration, to improve the patient compliance by developing Modified release matrix tablet of Bupropion Hydrochloride (BPH). Bupropion has been approved by the Food and Drug Administration (FDA) for use in smoking cessation. Eleven batches of matrix tablets of BPH were developed by using direct compression technique and coated with Opadry white. Compressed tablets were evaluated for weight variation, hardness, friability, similarity factor (f2) and in vitro dissolution using paddle (USP type II) method. Drug excipients compatibility study was also performed using differential scanning calorimetry (DSC). All the formulations were compared with the innovator. Among the eleven formulations F11 batch shows comparative dissolution profile with the innovator.